Nephrology
| IgA nephropathy
Nephrology
IgA nephropathy
Phase 2: Ravulizumab in IgAN – 50-week efficacy and safety results
book_2
Source:
Kidney Week 2024. Oral Session.
calendar_today
Published on Medfyle:
November 2024
import_contacts
5
min
In this medfyle
Early and meaningful reductions in proteinuria were demonstrated into Week 26 in the Phase 2 SANCTUARY trial; new data out to Week 50 now available, showing sustained effects and a trend towards eGFR stabilization.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: Efficacy and Safety of Ravulizumab in IgAN: Week 50 Results from a Phase 2 Randomized Controlled Trial. Tumlin J, et al. Presented at Kidney Week 2024; #FR-OR60.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
